A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer
Latest Information Update: 25 Nov 2023
At a glance
- Drugs Durvalumab (Primary) ; Fluorouracil; Mitomycin
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Rad-IO
Most Recent Events
- 20 Sep 2023 Planned End Date changed from 30 Apr 2028 to 30 Jun 2027.
- 13 Sep 2021 Planned End Date changed from 1 Dec 2027 to 30 Apr 2028.
- 12 Mar 2020 New trial record